Urology news for Saturday, October 24, 2026

Top 5 in urology

KEYNOTE-866: Perioperative pembrolizumab did not significantly improve event-free survival in cisplatin-eligible MIBC Phase 3 RCT · Ann Oncol · 2026-10-24
In this phase 3 trial of 907 cisplatin-eligible MIBC patients, adding perioperative pembrolizumab to neoadjuvant cisplatin-gemcitabine did not significantly improve 5-year event-free survival (63.5% vs 61.9%, HR 0.88) despite a higher pathologic complete response rate (44.4% vs 35.8%).
Why it matters: Contrasts with other perioperative immunotherapy regimens that have shown benefit in MIBC, highlighting that pCR gains do not always translate to survival benefit.
More Bladder cancer news
Final CA017-078 results: perioperative nivolumab plus chemo did not improve event-free survival in MIBC Phase 3 RCT · Ann Oncol · 2026-10-24
In this phase 3 trial of 653 patients with resectable MIBC, neoadjuvant nivolumab plus gemcitabine-cisplatin followed by adjuvant nivolumab improved pathologic complete response (39.1% vs 29.6%) but did not improve event-free survival compared to chemotherapy alone (HR 0.94) at a median follow-up of 54.5 months.
Why it matters: Adds to a mixed body of phase 3 evidence on perioperative checkpoint inhibition in MIBC, where pCR gains have not uniformly translated into event-free survival benefit.
More Bladder cancer news
Updated CAPItello-281 analysis shows OS benefit with capivasertib-abiraterone in PTEN-deficient mHSPC Retrospective · Ann Oncol · 2026-10-24
In an ad hoc, non-prespecified descriptive analysis of the phase 3 CAPItello-281 trial at 42% survival data maturity (median follow-up 39 months), capivasertib plus abiraterone showed an overall survival benefit over placebo plus abiraterone in PTEN-deficient de novo mHSPC (median 57.4 vs 46.5 months, HR 0.82, 95% CI 0.68-0.99, P=0.044), consistent with the updated radiographic progression-free survival benefit (HR…
Why it matters: A descriptive, non-prespecified interim update suggests a survival benefit in PTEN-deficient mHSPC; results are from an ad hoc analysis, not a prespecified final analysis.
More Prostate cancer news
Bipolar enucleation noninferior to TURP for 12-month symptom relief in RCT RCT · Eur Urol Focus · 2026-10-24
In an 84-patient two-center RCT, median 12-month IPSS was 5 in both bipolar enucleation (BipolEP) and TURP arms, meeting the noninferiority margin. BipolEP removed more tissue but had more early low-grade complications, while severe complications occurred only after TURP.
Why it matters: Supports BipolEP as an alternative to TURP for moderate-sized prostates with comparable symptom outcomes at one year.
More BPH and male LUTS news
FDA issues Class 2 recall of InterStim SureScan device FDA action · FDA · 2026-10-22
FDA has issued a Class 2 recall for the InterStim SureScan sacral neuromodulation system; specific defect and affected lots are detailed in the recall notice.
Why it matters: Providers implanting or following patients with InterStim SureScan devices should review the recall details for affected units.
More Female pelvic medicine and neurourology news

Prostate cancer news

Darolutamide plus ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer Study · The Manila Times · 2026-10-24
A phase 3 trial found that adding darolutamide to ADT and radiation therapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone in men with prostate cancer at high risk of recurrence.
Why it matters: A phase 3 trial found darolutamide plus ADT and radiation cut metastasis or death risk, which can be considered in high-risk recurrent prostate cancer pending full details.
Global prostate cancer cases projected to nearly double by 2050, GLOBOCAN review finds Review · Eur Urol · 2026-10-24
A GLOBOCAN-based review estimates 1.55 million new prostate cancer cases and 420,000 deaths worldwide in 2024, projecting 2.88 million cases and 924,000 deaths by 2050, with the largest relative mortality rise in Africa. The review also summarizes known risk factors including family history, germline variants, and smoking.
Why it matters: Highlights substantial and growing global disparities in prostate cancer burden tied to screening access and care equity.
Darolutamide linked to less cognitive change than enzalutamide in prostate cancer Study · Urology Times · 2026-10-23
A study comparing cognitive outcomes reported less cognitive change associated with darolutamide than with enzalutamide in men treated for prostate cancer.
Why it matters: Raises the question of differential CNS tolerability among androgen receptor inhibitors, relevant to treatment selection discussions.
Plasma proteins including ACP3 and ANXA2 linked to prostate cancer risk over a decade before diagnosis Prospective · Eur Urol · 2026-10-23
In a case-cohort study of EPIC and ARIC participants, several circulating proteins measured years before diagnosis, including ACP3, ANXA2, and KLK3, were associated with future prostate cancer risk, with some signals persisting beyond 15 years.
Why it matters: Suggests additional candidate blood biomarkers for prostate cancer risk stratification, but clinical assays and prospective validation are still needed.
Longer denosumab duration tied to higher jaw osteonecrosis but lower skeletal event risk in bone-metastatic prostate cancer Retrospective · JAMA Netw Open · 2026-10-23
In a Korean claims-based target trial emulation of 3,307 men with bone-metastatic castration-resistant prostate cancer, 3-year cumulative incidence was 9.8% for osteonecrosis of the jaw and 4.9% for skeletal events, with longer denosumab duration associated with higher ONJ risk relative to 6 months or less of treatment.
Why it matters: In this claims based study, longer denosumab duration tracked with more ONJ but fewer skeletal events, raising the question of how to balance these risks; claims data lack details like oral health status.
More intraoperative errors during nerve-sparing robotic prostatectomy linked to worse erectile function at one year Prospective · BJU Int · 2026-10-23
In a video-based analysis of 100 (subgroup 66 age-matched) bilateral nerve-sparing robotic prostatectomies by seven surgeons, cases resulting in erectile dysfunction at 12 months had 43% more total intraoperative errors and 67% more neurovascular bundle dissection errors than cases with good functional outcomes.
Why it matters: Suggests that objectively scored intraoperative performance during nerve-sparing dissection may be an important driver of postoperative potency outcomes.
Phase 3 trial analysis: Decipher score linked to differential abiraterone benefit Retrospective · The Manila Times · 2026-10-23
A secondary, biomarker-by-treatment interaction analysis of a phase 3 trial found the Decipher genomic classifier score was associated with differential benefit from adding abiraterone to ADT plus radiation in very high-risk localized prostate cancer. This is hypothesis-generating, not a prespecified validated predictive biomarker.
Why it matters: A biomarker-by-treatment interaction analysis in a phase 3 trial is hypothesis generating and needs prespecified validation before guiding abiraterone use in practice.
Review surveys blood and urine biomarkers for risk-stratified prostate cancer screening Review · Eur Urol Focus · 2026-10-23
This narrative review summarizes how PSA derivatives, multivariable blood tests (PHI, 4Kscore, Stockholm3, Proclarix), urine tests (SelectMDx, MyProstateScore 2.0, ExoDx, miR Sentinel) and MRI can be combined to refine prostate cancer early detection pathways.
Why it matters: Offers a framework for incorporating biomarkers and MRI into screening discussions, though ongoing trials are still optimizing specific pathways.
About 1 in 4 men with suspicious MRI and negative biopsy later found to have significant cancer Retrospective · Prostate · 2026-10-22
In a post hoc subgroup analysis of 153 men from the MULTIPROS trial with PI-RADS ≥3 lesions and an initial biopsy negative for clinically significant cancer, csPCa was later detected in 24.2%, three-quarters within 6 months.
Why it matters: Hypothesis generating only: early clustering of detections suggests possible initial sampling misses, but repeat-biopsy rates differed between groups making comparisons hard to interpret.

Bladder cancer news

ctDNA prognostic regardless of therapy received in cisplatin-eligible MIBC Retrospective · CancerNetwork · 2026-10-23
An analysis found circulating tumor DNA status was prognostic for outcomes irrespective of the perioperative therapy given in cisplatin-eligible muscle-invasive bladder cancer, according to the source headline.
Why it matters: Raises the question of ctDNA as a general prognostic biomarker in MIBC, though it does not establish predictive utility for selecting therapy.
Initial enfortumab vedotin dose reduction not clearly linked to worse survival in pretreated urothelial cancer Retrospective · JAMA Netw Open · 2026-10-23
In a multicenter Korean cohort of 368 patients with pretreated advanced urothelial carcinoma, physician-selected initial dose reduction of enfortumab vedotin showed no statistically significant difference in progression-free or overall survival compared with full dose, though confidence intervals were wide.
Why it matters: Raises the question of whether upfront dose reduction can preserve outcomes in selected patients, but this retrospective comparison cannot establish equivalence.
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC Intl regulatory · Urology Times · 2026-10-21
The European Commission approved the combination of perioperative pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer.
Why it matters: Adds a European regulatory pathway for a perioperative immunotherapy-ADC combination in MIBC, aligning with prior approvals in other regions.
Meta-analysis finds no significant survival difference for bladder-sparing vs early cystectomy in cT1 micropapillary cancer Meta-analysis · Eur Urol Oncol · 2026-10-21
Pooled data from 9 retrospective studies (1033 micropapillary cases) showed no statistically significant difference in cancer-specific survival between bladder-sparing approaches (mostly BCG) and early radical cystectomy for cT1 micropapillary urothelial carcinoma.
Why it matters: Raises the question of whether selected cT1 micropapillary patients could be managed with bladder-sparing therapy, but retrospective pooling limits causal inference.
Skin toxicity during first-line enfortumab vedotin-pembrolizumab linked to treatment outcomes in single-center cohort Retrospective · JAMA Netw Open · 2026-10-21
Among 185 patients with advanced urothelial carcinoma receiving first-line enfortumab vedotin plus pembrolizumab, over half developed treatment-emergent skin toxicity (rash or pruritus), most commonly within two weeks of starting therapy.
Why it matters: Single-center retrospective data raise the question of whether early skin toxicity tracks with outcomes on enfortumab vedotin-pembrolizumab, warranting prospective validation.
FDA accepts NDA for UGN-103 in recurrent low-grade intermediate-risk NMIBC FDA action · CancerNetwork · 2026-10-19
The FDA has accepted a new drug application for UGN-103 for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer; a decision is pending.
Why it matters: An approval could add another intravesical option for this NMIBC risk category.
NEITHER study finds inconsistent triage between NICE and EAU surveillance guidance in NMIBC Study · UroToday · 2026-10-19
The NEITHER study compared NICE and EAU recommendations for surveillance of non-high-risk NMIBC and found inconsistent triage, cost, and reliability between the two frameworks.
Why it matters: Highlights that guideline discordance between major societies can lead to variable surveillance intensity and resource use for the same patient.
Active surveillance explored as option after neoadjuvant chemo for muscle-invasive bladder cancer Study · Renal & Urology News · 2026-10-19
A report examines whether active surveillance may be feasible for select patients who respond well to neoadjuvant chemotherapy for muscle-invasive bladder cancer, as an alternative to immediate cystectomy or radiation.
Why it matters: Raises the question of whether bladder-preserving surveillance could apply more broadly, but requires prospective validation before practice change.

Kidney cancer news

Phase 3 trial opens testing benmelstobart-anlotinib vs sunitinib in non-clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-20
A phase 3 trial will randomize 126 patients with advanced non-clear cell renal cell carcinoma (excluding chromophobe, collecting duct, and medullary subtypes) 2:1 to benmelstobart plus anlotinib versus sunitinib, with progression-free survival as the primary endpoint.
Meta-analysis: neoadjuvant therapy enables partial nephrectomy in 80% of selected RCC cases Meta-analysis · Clin Genitourin Cancer · 2026-10-20
A systematic review and single-arm meta-analysis of 34 studies found pooled rates of 80% for achieving partial nephrectomy, 32% objective response, and 11% pathologic complete response after neoadjuvant systemic therapy in localized/locally advanced RCC, with grade 3+ treatment-related adverse events in 28%.
Why it matters: Suggests neoadjuvant therapy may help enable nephron-sparing surgery in select RCC patients, though evidence certainty was low given the single-arm design.

Upper tract urothelial carcinoma news

UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08
Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).
Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.
EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Commentary: why the PUSH hydration trial found no benefit despite decades of stone prevention advice Commentary · Kidney Int · 2026-10-22
A commentary on the PUSH trial (n=1658) notes its behavioral hydration intervention did not significantly reduce stone recurrence, likely due to poor adherence and only a minimal urine volume difference versus controls, contrasting with the 1996 Borghi trial where sustained high urine output did reduce recurrence.
Why it matters: Suggests that advising hydration alone without structured adherence support may not translate into the urine volume increases needed for stone prevention.
Meta-analysis: no overall SFR difference between primary and delayed ureteroscopy for obstructing stones Meta-analysis · Eur Urol Open Sci · 2026-10-21
Pooled data from 15 studies (19,907 patients) found no significant difference in stone-free rates between primary ureteroscopy (within 24-48 hours) and delayed ureteroscopy (OR 1.20, 95% CI 0.75-1.92, I2=86%). In a subgroup of 5 studies using a zero-fragment imaging definition, primary URS had higher odds of stone-free status (OR 1.49, 95% CI 1.10-2.02); a sensitivity analysis of 2 CT-based trials with strict…
Why it matters: Supports flexibility in ureteroscopy timing overall, but the zero-fragment subgroup signal favoring primary URS stems from few studies and needs confirmation given heterogeneity in the full analysis.
Transient apnoea during ureteroscopic lithotripsy speeds stone clearance RCT · BJU Int · 2026-10-19
In a 150-patient three-arm trial, transient apnoea during flexible ureteroscopic laser lithotripsy improved active lithotripsy efficiency versus regular ventilation and small tidal-volume ventilation, with shorter operative time and better surgeon-rated stability, though stone-free rates were similar across groups.
Why it matters: Suggests an anesthesia-based technique to reduce operative time without added bleeding/complication risk, worth discussing with anesthesia teams.
Evidence map charts rapid growth of suction ureteroscopy research, mostly retrospective and single-center Review · BJU Int · 2026-10-18
A systematic evidence map of 154 studies (2022-2026) on suction ureteric access sheaths and direct-in-scope suction found publications rose sharply, led by China, with retrospective comparative studies dominating and only 11 RCTs identified.
Why it matters: Highlights that despite growing adoption of suction-assisted ureteroscopy, high-quality randomized evidence remains limited.

BPH and male LUTS news

Meta-analysis: early apical release technique reduces short-term incontinence after HoLEP Meta-analysis · Prostate Cancer Prostatic Dis · 2026-10-21
Pooling 5 studies (2821 patients), early apical release during HoLEP was associated with lower rates of stress incontinence at 4-6 weeks and 3-4 months versus conventional technique, with no difference by 6-12 months and similar functional outcomes overall.
Why it matters: Suggests early apical release may speed continence recovery after HoLEP without compromising later functional outcomes, pending confirmation in controlled trials.
Mini-HoLEP improves early continence recovery versus standard HoLEP in RCT Prospective · Eur Urol Open Sci · 2026-10-19
In a 90-patient randomized trial, mini-HoLEP using a 22-Fr resectoscope reduced urinary incontinence at 1 month (22.2% vs 51.1%) and 2 months versus standard 26-Fr HoLEP, with no significant difference in long-term continence or complications.
Why it matters: Offers a technical modification that may speed early continence recovery after HoLEP without compromising long-term outcomes.

Female pelvic medicine and neurourology news

FDA issues Class 2 recall of PNE Lead Implant Kit FDA action · FDA · 2026-10-17
FDA has classified a recall of a percutaneous nerve evaluation (PNE) lead implant kit as Class 2, a device category used in sacral neuromodulation testing for voiding dysfunction.
Why it matters: Urologists using PNE leads for sacral neuromodulation trials should check whether affected lots are in their inventory.

Reconstruction and trauma news

Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14
A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…
Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.
Systematic review: incisional hernia after robotic prostatectomy varies widely, linked to extraction site Review · Eur Urol Open Sci · 2026-10-12
Across 16 mostly retrospective studies (56,661 patients), reported incisional hernia after minimally invasive radical prostatectomy ranged from 0.04% to 31%. Two comparative studies found lower rates with Pfannenstiel than periumbilical extraction, and three registry studies reported lower rates after open surgery than after MIRP. Evidence is limited by heterogeneous definitions and follow-up.
Why it matters: Observational data suggest specimen extraction site and surgical approach may influence incisional hernia risk after robotic prostatectomy, but evidence is heterogeneous and not yet definitive.
Augmentation cystoplasty shows durable urodynamic benefit over median 19 years in spinal cord injury Retrospective · BJU Int · 2026-10-10
In a retrospective cohort of 70 patients with spinal cord injury and refractory neurogenic bladder dysfunction, augmentation cystoplasty increased mean bladder capacity from 155 to 490 mL and reduced detrusor pressure from 72 to 19 cmH2O, with continence achieved in 67% over a mean 19-year follow-up; complications included urolithiasis (10%) and malignancy (4%).
Why it matters: Provides long-term reassurance on durability and complication rates for augmentation cystoplasty in a population with limited surgical alternatives.
Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.

Men's health news

Markov model suggests male-first evaluation may reduce cost and time to pregnancy in varicocele-related infertility Study · J Urol · 2026-10-24
A theoretical discrete-time Markov model comparing four infertility treatment strategies in couples with male varicocele found that male-first evaluation modestly reduced cost and time to pregnancy compared to current practice when repair efficacy was at least 5%, though immediate ART shortened time to pregnancy at 40-80% higher cost.
Why it matters: A modeling study, not clinical trial data, suggesting male-first evaluation could be cost-conscious in select varicocele-related infertility cases pending real-world validation.
Meta-analysis quantifies modest, highly variable gains from penile augmentation procedures Meta-analysis · Int J Impot Res · 2026-10-18
Pooled data from 30 studies (2554 patients) showed girth increases of roughly 1.9-2.0 cm with fillers or grafts and length gains of 1.4-2.2 cm, but extreme heterogeneity and wide prediction intervals mean individual outcomes vary greatly.
Why it matters: Provides realistic outcome ranges for counseling patients considering penile augmentation, emphasizing uncertainty over pooled averages.

Pediatric urology news

AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
Higher chemotherapy dose and testicular radiation linked to abnormal pubertal hormone patterns in childhood cancer survivors Retrospective · JAMA Netw Open · 2026-10-10
In a cohort of 221 male childhood cancer survivors, cumulative alkylating chemotherapy dose and testicular radiotherapy above 1 Gy were associated with dose-dependent elevations in pubertal FSH levels, a marker of impaired gonadal function.
Why it matters: Suggests cumulative alkylator and testicular radiation dose track with gonadal dysfunction, which may help identify survivors for earlier fertility discussions.
Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Raises the question of whether temporary vesicostomy reduces early complications after augmentation; retrospective comparison cannot exclude selection differences.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

Technology and AI news

NICE recommends five AI tools for prostate cancer screening pathways Intl regulatory · BMJ · 2026-10-24
The UK's NICE has recommended five artificial intelligence tools for use in prostate cancer screening pathways, according to a BMJ news report. Details on the specific tools, evidence base, and conditions of use were not specified in the available source.
Why it matters: UK health body NICE recommends five AI programs for use in prostate cancer screening pathways, per a BMJ report.

More urology news

No difference in complication or readmission rates by PA versus NP staffing after radical prostatectomy Retrospective · JU Open Plus · 2026-10-23
In a Medicare 20% sample of 8,975 men undergoing radical prostatectomy across 424 urology groups, postoperative complications, prolonged length of stay, and 90-day readmission did not differ significantly between practices staffed with PAs only, NPs only, or both.
Why it matters: Raises the question of whether PA and NP staffing models can be considered interchangeable for this operation, though this is hypothesis generating from Medicare claims data that lack clinical granularity.
Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16
A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.
Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.

Loading today's edition…